Search the Newsreel

Thin Float, Heavy Overhang: Analyst Warns Gyre Therapeutics’ Concentrated Ownership and Pledged Shares Heighten Liquidity and Control Risks

An analyst has issued a warning regarding Gyre Therapeutics Inc. (GYRE), citing its thinly traded common stock and concentrated ownership as significant risks. This structure heightens liquidity concerns, as any large share sale could drastically impact the stock price, and the pledging of shares …

Gyre Therapeutics earnings missed by $0.06, revenue topped estimates

Gyre Therapeutics (NASDAQ: GYRE) reported its second-quarter earnings, missing analyst EPS estimates by $0.06 with an EPS of $-0.1200. However, the company's revenue of $29.1 million surpassed the consensus estimate of $26.49 million. The stock has seen negative performance over the last three and …

Gyre Therapeutics Releases Q2 2026 Financial Results

Gyre Therapeutics reported a non-GAAP adjusted loss of $0.12 per share and revenue of $29.1M for Q2 2026. Despite a 2.0% decline in overall revenue year-over-year due to market challenges, its flagship product ETUARYTM saw a 19.1% increase, generating $28.0M. Wall Street analysts maintain …

Gyre Therapeutics reports Q2 2026 revenue $29.1M, GAAP EPS $(0.12); full-year revenue guidance affirmed

Gyre Therapeutics announced its Q2 2026 financial results, reporting revenue of $29.1 million and a GAAP basic loss per share of $0.12. The company reaffirmed its full-year 2026 revenue guidance of $100.5–$111.0 million and highlighted the completion of its acquisition of Cullgen, as well …

Gyre Therapeutics (NASDAQ:GYRE) Issues Earnings Results

Form 8K Gyre Therapeutics Inc For: 7 August By Investing.com

This article reports on the filing of a Form 8K by Gyre Therapeutics Inc. on August 7th. It includes various financial market data and popular news headlines, but no specific details from the Form 8K itself. The content primarily serves as a placeholder or …

Gyre Therapeutics (NASDAQ: GYRE) swings to 32,849 H1 2026 net loss

GYRE Stock Price and Chart — NASDAQ:GYRE

This article provides a detailed overview of Gyre Therapeutics, Inc. (NASDAQ: GYRE), a biopharmaceutical company focused on organ fibrosis and inflammatory diseases. It includes key financial metrics, stock performance data, analyst ratings, and answers to frequently asked questions about the company's stock, earnings, and …

Gyre Therapeutics Q2 EPS misses estimate despite sales beat

Gyre Therapeutics Reports Second Quarter 2026

The article "Gyre Therapeutics Reports Second Quarter 2026" is the full title of the provided document. There is no additional content to summarize, as the document body is empty.

Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview

Gyre Therapeutics, Inc. is projected to report a loss of 13 cents per share. This earnings preview is based on information from Refinitiv. The full article provides more in-depth analysis for investors and stakeholders.

Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates

GYRE Q2 Revenue Falls To $29.1 Million As Net Loss Widens

Gyre Therapeutics (GYRE) reported a Q2 2026 revenue of $29.1 million, a decrease from the previous year, with a widening GAAP net loss of $14.3 million. Despite the revenue fall, the company reaffirmed its full-year 2026 revenue guidance and highlighted the acceptance of NDA …

Gyre Therapeutics, Inc. Affirms Earnings Guidance for the Full Year of 2026

Gyre Therapeutics (GYRE) awards director 40,000 stock options vesting to 2029

Gyre Therapeutics (GYRE) director Kirkby Maxwell was granted 40,000 stock options on August 3, 2026, with an exercise price of $6.11 per share and an expiration date of August 3, 2036. The options will vest in 36 equal monthly installments through August 3, 2029, …

Weston Claire files initial ownership report at Gyre Therapeutics (GYRE)

Gyre Therapeutics director Weston Claire has filed an initial Form 3, an ownership report indicating beneficial ownership status. The report lists Claire as a director but shows no reported transactions or share holdings at this time. The filing includes a Power of Attorney authorizing …

Gyre Therapeutics (GYRE) director discloses no stock ownership

Gyre Therapeutics, Inc. reported an initial statement of beneficial ownership for director Kirkby Maxwell, indicating he holds no stock, derivative securities, or has had any transactions in the company. This Form 3 filing clarifies his role as a director without executive function or significant …

GYRE THERAPEUTICS, INC. SEC Filing (Aug 4, 2026)

This article reports on an SEC filing by GYRE THERAPEUTICS, INC. (GYRE) related to a Notice of Effectiveness for an S-3 form, effective August 3, 2026. The filing was accepted by SEC EDGAR on August 4, 2026. The article also provides an overview of …

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (NASDAQ:GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm

Kaskela Law LLC has announced an investigation into Gyre Therapeutics, Inc. (NASDAQ:GYRE) on behalf of its long-term investors. The investigation aims to determine if Gyre's officers and directors violated securities laws or breached fiduciary duties through recent corporate actions. Long-term shareholders are encouraged to …

Gyre Therapeutics Inc (GYRE) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Gyre Therapeutics Inc (GYRE), highlighting its current risk score of 3.28 and its ranking within the Biotechnology & Medical Research industry. It details the company's beta value of 1.85, indicating high volatility compared to the S&P 500, …

Gyre Therapeutics Inc (GYRE) Financial Health: Profitability & Balance Sheet Analysis

Gyre Therapeutics Inc (GYRE) shows a robust financial status with a score of 8.06, ranking well within its industry. The company reported significant growth in its latest quarter, with revenue increasing by 2.09% and net profit soaring by 422.13% year-over-year. While overall financial health …

GYRE|Gyre Therapeutics Inc|Price:5.985|Chg%:-0.145

This article provides a comprehensive stock analysis of Gyre Therapeutics Inc. (GYRE), highlighting its healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. It details the company's biopharmaceutical portfolio, including F351 for MASH-associated fibrosis and various products …

Gyre Therapeutics Inc (GYRE) Valuation: PE, PB & Fair Value Analysis

This article analyzes the valuation of Gyre Therapeutics Inc (GYRE), reporting its current valuation score as 7.76, placing it 196th out of 384 in its industry. The company's P/E ratio is noted as -80.43, and it states that P/E, P/B, P/S, and P/CF relevant …

Gyre Therapeutics Inc (GYRE) Institutional Confidence

Gyre Therapeutics Inc (GYRE) has an institutional shareholding score of 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 4.74%, showing a 36.23% increase quarter-over-quarter. Key institutional shareholders include GNI Group Ltd, Ma …

Gyre Therapeutics Inc (GYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Gyre Therapeutics Inc (GYRE). It indicates that the company has distributed $0.00 in dividends over the past five years and details multiple 15-to-1 merger-related stock splits that occurred on October 30, 2023. The stock …

Gyre Therapeutics Inc (GYRE) Income Statement

This article provides the quarterly and annual income statements for Gyre Therapeutics Inc (GYRE), offering detailed financial data such as total revenue, operating expenses, net income, and earnings per share spanning several fiscal quarters and years. It also includes an FAQ section explaining how …

Cash flow from financing activities of Gyre Therapeutics Inc – GETTEX:L9S

This article provides financial data for Gyre Therapeutics Inc, specifically focusing on its cash flow from financing activities. The content shows a heading for this financial metric, indicating that data for various periods, values, and changes would typically be displayed here. The page appears …

Gyre Therapeutics, Inc. Revenue Breakdown – NASDAQ:GYRE

Gyre Therapeutics, Inc. (NASDAQ: GYRE) reported a total revenue of $116.59 million USD last year. The majority of this revenue, $116.59 million USD, came from its top-performing segment, Gyre Pharmaceuticals, primarily contributed by operations in China. This marks an increase from the $105.76 million …

Return on assets % of Gyre Therapeutics Inc – MUN:L9S

This article provides financial information for Gyre Therapeutics Inc (MUN:L9S) on the Munich Stock Exchange, specifically focusing on its Return on Assets percentage. It is presented on the TradingView platform, which offers comprehensive market data and tools. The content includes general financial overview, with …

Gyre Therapeutics Inc Statistics – MUN:L9S

This article provides key financial statistics and ratios for Gyre Therapeutics Inc (MUN:L9S). It highlights that the company has a price-to-sales ratio of 4.62 and an enterprise value to EBITDA ratio of 131.53, employing 625 people as of 2025. The content also presents a …

Total debt per share of Gyre Therapeutics Inc – MUN:L9S

The article presents financial information for Gyre Therapeutics Inc (MUN:L9S), specifically focusing on its total debt per share. It indicates that the market is closed, with no trades reported, and provides navigation to further financial data, community insights, forecasts, ETFs, and market information on …

Gyre Therapeutics, Inc. (L9S.F) Analyst insights, Price targets and Recommendations

This article provides analyst insights, price targets, and recommendations for Gyre Therapeutics, Inc. (L9S.F), listed on the Frankfurt exchange. It highlights recent analyst initiations with "Buy" ratings from Jefferies and HC Wainwright & Co., along with current stock performance and related tickers.

Gyre Therapeutics Strengthens Board with New Director Appointments

Gyre Therapeutics has announced the appointment of three new directors to its board: Chief Scientific Officer Yue Xiong, Ph.D., consultant Maxwell Kirkby, and AI healthcare executive Claire Weston, Ph.D., effective August 1, 2026. These appointments aim to enhance the company's scientific expertise, clinical development, …